• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    6/14/24 4:34:22 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OLMA alert in real time by email
    SC 13G 1 p24-2172sc13g.htm OLEMA PHARMACEUTICALS INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  )*
     

    Olema Pharmaceuticals, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    68062P106

    (CUSIP Number)
     

    June 4, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

     

     

    CUSIP No. 68062P10613GPage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,225,250

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,225,250

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,225,250

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 68062P10613GPage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,225,250

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,225,250

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,225,250

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 68062P10613GPage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,225,250

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,225,250

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,225,250

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 68062P10613GPage 5 of 7 Pages

     

     

     

    Item 1(a). Name of Issuer.
       
      Olema Pharmaceuticals, Inc. (the “Issuer”).
       
    Item 1(b). Address of Issuer's Principal Executive Offices.
       
      780 Brannan Street, San Francisco, CA 94103.

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
      Cubist Systematic Strategies, LLC, an advisor under common control with Point72 Asset Management, acts as a sub-advisor with respect to a portion of the Shares reported herein.
     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

     

    Item 2(b). Address of Principal Business Office.
       
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
       
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
       
      Common Stock, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number.
       
      68062P106

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
       
      Not applicable.

     

     

    CUSIP No. 68062P10613GPage 6 of 7 Pages

     

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on June 13, 2024.

     

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

     

    The aggregate percentage of Shares reported to be beneficially owned by each Reporting Person is based on 56,978,527 Shares outstanding which is the sum of (i) 55,933,827 Shares outstanding as of May 3, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on May 8, 2024; and (ii) 1,044,700 Shares purchased by Point 72 Associates in the at the market offering disclosed in the Issuer’s Prospectus filed pursuant to Rule 424(b)(5) with the SEC on January 5, 2024.

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 68062P10613GPage 7 of 7 Pages

     

       

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: June 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
     

    Title: Authorized Person

     

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

    Get the next $OLMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLMA

    DatePrice TargetRatingAnalyst
    4/2/2024$24.00Buy
    Goldman
    1/30/2024$20.00Buy
    Citigroup
    7/21/2023$21.00Outperform
    Oppenheimer
    5/5/2023$16.00Overweight
    CapitalOne
    2/22/2023$12.00Outperform
    Credit Suisse
    7/6/2022$16.00Buy
    Canaccord Genuity
    6/9/2022$12.00Neutral → Buy
    H.C. Wainwright
    2/28/2022Neutral
    HC Wainwright & Co.
    More analyst ratings

    $OLMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Olema Pharmaceuticals with a new price target

      Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      4/2/24 7:41:58 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Olema Pharmaceuticals with a new price target

      Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      1/30/24 7:36:41 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Olema Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00

      7/21/23 7:55:18 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Olema Oncology Reports First Quarter 2025 Financial and Operating Results

      Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models; Phase 1 trial recruitment ongoingEnded the first quarter with $392.7 million in cash, cash equivalents, and marketabl

      5/13/25 4:01:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference Date: Tuesday, May 20, 2025 at 4:30 p.m. ETFormat: Fireside Chat Location: New York, NY T.D. Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO and EHADate: Tuesday, May 27, 2025 at 5 p.m. ETFormat: Fireside ChatLocation: Virtual Live webcasts and recor

      5/9/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wit

      5/2/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Olema Pharmaceuticals Inc.

      10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      5/13/25 4:15:24 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      5/13/25 4:05:11 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Olema Pharmaceuticals Inc.

      DEFA14A - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      4/28/25 4:35:04 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      1/13/25 4:34:40 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/18/24 6:52:04 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/17/24 7:52:19 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

      SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/11/24 4:30:15 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

      SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/4/24 7:49:50 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

      SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      11/14/24 4:34:56 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Graham G. Walmsley

      4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      5/13/25 7:14:52 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CH. DISCOV. & NON-CLIN DEV OFF Myles David C.

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:20:52 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Zojwalla Naseem

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:19:32 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Financials

    Live finance-specific insights

    See more
    • Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

      Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),

      12/10/24 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

      SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien

      11/25/24 5:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

      Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the

      5/15/24 7:01:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Leadership Updates

    Live Leadership Updates

    See more
    • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

      3/4/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

      SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

      2/18/25 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)